Image courtesy of Ablative Solutions
February 12, 2015 — Ablative Solutions Inc. announced the addition of Michael Weber, M.D., FACP, FACC, FAHA, to its Scientific Advisory Board. Weber is a distinguished expert in the areas of hypertension and preventive cardiology. He is currently Professor of Medicine at SUNY Downstate College of Medicine in Brooklyn, New York. He is the editor-in-chief of The Journal of Clinical Hypertension. Weber was one of the founders of The American Society of Hypertension and has served as its President.
Ablative Solutions has developed a patented device, the Peregrine System, which is a percutaneous catheter designed to deliver diagnostic and therapeutic agents through vessel walls to the outer region of arteries. The Peregrine System has been cleared by the U.S. Food and Drug Administration (FDA) for the infusion of diagnostic and therapeutic agents into the perivascular area.
Ablative Solutions is currently investigating the use of the Peregrine System in a clinical study in Europe intended to secure a CE Mark. The System is being evaluated for renal denervation, providing a treatment that delivers therapy directly to the nerves that run along the perimeter of the renal artery. The interruption of these nerve pathways may have therapeutic implications for hypertension, metabolic syndrome, congestive heart failure and obesity. The system is not currently cleared or approved in the United States for renal denervation, or for the treatment of hypertension, metabolic syndrome, congestive heart failure or obesity.
For more information: www.ablativesolutions.com